Reduced-intensity unrelated cord blood transplantation for treatment of metastatic renal cell carcinoma: First evidence of cord-blood-versus-solid-tumor effect

Bone Marrow Transplantation

Volumn 38, Issue 11, 2006, Pages 729-732

  Takami, A ^a   Takamatsu, H ^a   Yamazaki, H ^a   Ishiyama, K ^a   Okumura, H ^a   Ohata, K ^a   Konaka, H ^a   Asakura, H ^a   Namiki, M ^a   Nakao, S ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; FLUDARABINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TSUKUBAENOLIDE;

ACUTE GRAFT VERSUS HOST DISEASE; AGED; ARTICLE; CANCER REGRESSION; CASE REPORT; CLINICAL PROTOCOL; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG TOLERABILITY; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; MALE; METASTASIS; NEPHRECTOMY; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING;

AGED; CARCINOMA, RENAL CELL; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33751027512     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705519     Document Type: Article

References (30)

1. Gommersall L, Hayne D, Lynch C, Joseph JV, Arya M, Patel HR. Allogeneic stem-cell transplantation for renal-cell cancer. Lancet Oncol 2004; 5: 561-567.
2. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 1928-1935.
3. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
4. Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer 2005; 104: 2099-2103.
5. Rzepecki P, Zolnierek J, Sarosiek T, Langiewicz P, Szczylik C. Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma - single center experience. Neoplasma 2005; 52: 238-242.
6. Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: Toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004; 10: 7799-7811.
7. Artz AS, Van Besien K, Zimmerman T, Gajewski TF, Rini BI, Hu HS et al. Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago experience. Bone Marrow Transplant 2005; 35: 253-260.
8. Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: Single institution experience with a minimum 1-year follow-up. Exp Hematol 2004; 32: 599-606.
9. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3836.
10. Rini BI, Halabi S, Barrier R, Margolin KA, Avigan D, Logan T et al. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: A CALGB intergroup phase II study. Biol Blood Marrow Transplant 2006; 12: 778-785.
11. Massenkeil G, Roigas J, Nagy M, Wille A, Stroszczynski C, Mapara MY et al. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: Delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 2004; 34: 309-316.
12. Hentschke P, Barkholt L, Uzunel M, Mattsson J, Wersall P, Pisa P et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253-261.
13. Pedrazzoli P, Da Prada GA, Giorgiani G, Schiavo R, Zambelli A, Giraldi E et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: A pilot study in patients with refractory malignancies. Cancer 2002; 94: 2409-2415.
14. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
15. Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: Feasibility, engraftment, and clinical results. J Clin Oncol 2002; 20: 2017-2024.
16. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001; 344: 1815-1822.
17. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-2275.
18. Miyakoshi S, Yuji K, Kami M, Kusumi E, Kishi Y, Kobayashi K et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res 2004; 10: 3586-3592.
19. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276-2285.
20. Sanz GF, Saavedra S, Planelles D, Senent L, Cervera J, Barragan E et al. Standardized, unrelated donor cord blood transplantation in adults with hematologic malignancies. Blood 2001; 98: 2332-2338.
21. Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004; 104: 3813-3820.
22. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Miller JS, Wagner JE. Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood 2003; 102: 1915-1919.
23. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
24. Childs RW, Srinivasan R. Allogeneic hematopoietic cell transplantation for solid tumors. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing: Malden, 2004, pp 1177-1187.
25. Barker JN, Wagner JE. Umbilical-cord blood transplantation for the treatment of cancer. Nat Rev Cancer 2003; 3: 526-532.
26. Broxmeyer HE, Douglas GW, Hangoc G, Cooper S, Bard J, English D et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci USA 1989; 86: 3828-3832.
27. Morecki S, Moshel Y, Gelfend Y, Pugatsch T, Slavin S. Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma. Int J Cancer 1997; 71: 59-63.
28. Morecki S, Yacovlev E, Diab A, Slavin S. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res 1998; 58: 3891-3895.
29. Mommaas B, Stegehuis-Kamp JA, van Halteren AG, Kester M, Enczmann J, Wernet P et al. Cord blood comprises antigen-experienced T cells specific for maternal minor histocompatibility antigen HA-1. Blood 2005; 105: 1823-1827.
30. Mommaas B, van Halteren AG, Pool J, van der Veken L, Wieles B, Heemskerk MH et al. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica 2005; 90: 1415-1421.